Key result
Sevoflurane significantly protected against myocardial ischemia-reperfusion injury by inhibiting USP7, destabilizing PTEN, activating the PI3K/AKT pathway, and suppressing ferroptosis.
Why the study?
Myocardial ischemia-reperfusion injury remains a significant challenge in acute myocardial infarction, creating a need to investigate whether sevoflurane mitigates ferroptosis via the USP7-mediated PTEN/PI3K/AKT pathway.
Does sevoflurane reduce myocardial ischemia-reperfusion injury in rat models?
Does sevoflurane reduce myocardial ischemia-reperfusion injury in rat models?
p-value: p=<0.0001
Sevoflurane protects against myocardial ischemia-reperfusion injury by inhibiting USP7, destabilizing PTEN, activating the PI3K/AKT pathway, and suppressing ferroptosis.
Should not change clinical practice in acute MI; leaves open mechanistic role of USP7/PTEN pathway in ferroptosis.
Background and Objective: Myocardial ischemia-reperfusion (I/R) injury remains a significant challenge in the treatment of acute myocardial infarction, highlighting the urgent need for effective cardioprotective strategies. Sevoflurane (Sev), a widely used anesthetic, has demonstrated notable cardioprotective potential. This study investigated whether Sev mitigates ferroptosis in myocardial cells by inhibiting the USP7-mediated PTEN/PI3K/AKT pathway. Methods: Rat myocardial I/R injury and H9c2 cell hypoxia/reoxygenation (H/R) injury models were established. Myocardial injury was assessed through cTnT levels, hemodynamic parameters, and histological analyses. Cell viability, LDH release, TUNEL staining, and ferroptosis markers (GSH, MDA, Fe² + , ROS) were evaluated. Co-IP and CHX assays were employed to explore USP7’s regulation of PTEN stability. Results: Sev significantly reduced serum cTnT levels, improved hemodynamic function, decreased infarct size, and alleviated myocardial fibrosis and inflammation in rats subjected to I/R injury. In H9c2 cells, Sev enhanced cell viability and suppressed apoptosis. Sev reversed hypoxia/reoxygenation (H/R)-induced USP7 overexpression and ferroptosis, whereas USP7 overexpression attenuated Sev’s protective effects. Conclusion: Sev protected against myocardial I/R injury by inhibiting USP7, destabilizing PTEN, activating the PI3K/AKT pathway, and suppressing ferroptosis. These findings elucidated the molecular mechanism of Sev’s cardioprotective effect and suggested USP7 as a potential therapeutic target for myocardial protection.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied Myocardial ischemia-reperfusion injury (n=70). Sevoflurane vs. Ischemia-reperfusion without sevoflurane was evaluated on Myocardial injury assessed by serum cTnT levels, infarct size, and hemodynamic parameters (p=<0.0001). Sevoflurane significantly protected against myocardial ischemia-reperfusion injury by inhibiting USP7, destabilizing PTEN, activating the PI3K/AKT pathway, and suppressing ferroptosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: